rAAV Vector GLA Gene Delivery for Fabry Disease Neuropathy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Fabry disease, such as enzyme replacement therapy, require lifelong administration and do not halt or reverse disease progression, particularly affecting the nervous system.
Innovation Solution
The use of recombinant adeno-associated viral vectors (rAAV) to mediate the transfer and expression of the α-Galactosidase A (GLA) gene, leading to sustained exposure of functional α-GAL enzyme in multiple tissues, including the nervous system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy is used to treat Fabry disease, then symptoms are resolved and enzyme activity is restored, but treatment requires lifelong intravenous administration and does not stop disease progression
Solution Approach 1:
The patent delivers the functional GLA gene into patient cells in advance, establishing endogenous enzyme production capacity before disease progression occurs. This preliminary genetic intervention enables cells to continuously produce α-GAL enzyme without requiring repeated external administrations, thereby resolving symptoms while preventing future disease progression.
Solution Approach 2:
The patent enables patient cells to self-produce the functional α-GAL enzyme through integrated GLA gene expression. Instead of relying on continuous external enzyme replacement therapy, the modified cells autonomously synthesize the needed enzyme, eliminating the need for lifelong intravenous administrations and stopping disease progression at the genetic level.
2Reliability
If enzyme replacement therapy is administered, then α-GAL enzyme activity is restored, but circulatory half-life is short and cellular delivery is suboptimal
Solution Approach 1:
The patent uses a viral vector as an intermediary carrier to deliver the GLA gene directly into patient cells. This vector-mediated approach bypasses the limitations of circulatory half-life and cellular delivery associated with intravenous enzyme administration, enabling efficient gene transfer and sustained endogenous enzyme production.
Solution Approach 2:
The patent establishes permanent genetic capacity for enzyme production through preliminary gene delivery. By integrating the GLA gene into patient cells upfront, the system eliminates the need for continuous enzyme replacement and overcomes the short circulatory half-life limitation, as the cells continuously produce enzyme internally.
3Reliability
If gene therapy using rAAV vector is used to achieve sustained enzyme exposure, then disease progression stops and neuropathy is ameliorated, but treatment complexity increases
Solution Approach 1:
The patent enables patient cells to self-produce the functional α-GAL enzyme through integrated GLA gene expression. This self-service approach stops disease progression by establishing permanent endogenous enzyme production, eliminating the need for complex lifelong treatments while requiring only a single gene delivery intervention.
Data Source
AI summary
The present disclosure provides, among other things, gene therapy approaches of treating Fabry disease in a subject, particularly for alleviating periphery neuropathy associated with Fabry disease. The method comprises administering to a subject in need thereof a recombinant adeno-associated viral vector (rAAV) packaged in an AAV capsid having broad tissue tropism, and expressing a GLA transgene with improved stability and lowered immunogenicity.